Clinical Scorecard: Utilizing Explainable AI for Enhanced Precision in Clinical Trial Participant Selection: A Case Study of the NetraAI Platform in a Phase II Study on Depression

At a Glance

Key Highlights

• NetraAI improves predictive accuracy by approximately 25-30% over traditional machine learning models in identifying treatment responders.
• NetraAI identifies minimal variable combinations (e.g., 10 clinical variables or 8 MRI features) that achieve high predictive performance and specificity.
• Explainable AI approach enables discovery of clinically meaningful patient subgroups (Personas) for prospective trial enrichment and personalized medicine.

Guideline-Based Recommendations

Diagnosis

• Utilize high-dimensional clinical and imaging data to characterize patient heterogeneity in treatment-resistant depression.
• Apply explainable AI methods like NetraAI to identify subpopulations with differential treatment responses.

Management

• Incorporate AI-derived patient subgroups (Personas) to prospectively enrich clinical trial cohorts with likely responders.
• Use minimal variable sets identified by AI for streamlined patient screening and inclusion/exclusion criteria.

Monitoring & Follow-up

• Validate AI-identified subpopulations through internal bootstrapping and holdout methods to ensure robustness.
• Monitor predictive performance metrics such as AUC, sensitivity, specificity during trial enrollment.

Risks

• Be cautious of traditional univariate subgroup analyses that may lack power and interpretability.
• Avoid black-box AI models lacking explainability which may limit clinical and regulatory acceptance.

Patient & Prescribing Data

Patients with treatment-resistant depression enrolled in Phase II ketamine trials

NetraAI enables identification of patients most likely to benefit from ketamine therapy by analyzing psychiatric scales and MRI features, improving trial success potential and enabling personalized treatment approaches.

Clinical Best Practices

• Leverage explainable AI platforms that integrate multi-modal data for patient stratification in clinical trials.
• Use minimal, interpretable variable combinations to define patient subgroups to facilitate clinical and regulatory decision-making.
• Prospectively apply AI-derived inclusion/exclusion criteria to enrich trial populations and enhance statistical power.

References

• Clinical trial failures and patient heterogeneity
• AI and machine learning challenges in psychiatry
• Explainable AI in clinical trials